Lewis Clayton Jr. Cantley Sells 4,000 Shares of Agios Pharmaceuticals, Inc. (AGIO) Stock

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Director Lewis Clayton Jr. Cantley sold 4,000 shares of the company’s stock in a transaction dated Thursday, September 14th. The stock was sold at an average price of $65.59, for a total transaction of $262,360.00. Following the transaction, the director now owns 86,394 shares in the company, valued at $5,666,582.46. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Lewis Clayton Jr. Cantley also recently made the following trade(s):

  • On Wednesday, September 13th, Lewis Clayton Jr. Cantley sold 1,000 shares of Agios Pharmaceuticals stock. The stock was sold at an average price of $65.47, for a total transaction of $65,470.00.
  • On Wednesday, August 23rd, Lewis Clayton Jr. Cantley sold 4,000 shares of Agios Pharmaceuticals stock. The stock was sold at an average price of $56.85, for a total transaction of $227,400.00.
  • On Wednesday, July 19th, Lewis Clayton Jr. Cantley sold 3,500 shares of Agios Pharmaceuticals stock. The stock was sold at an average price of $56.14, for a total transaction of $196,490.00.
  • On Thursday, July 20th, Lewis Clayton Jr. Cantley sold 9,000 shares of Agios Pharmaceuticals stock. The stock was sold at an average price of $56.36, for a total transaction of $507,240.00.

Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) opened at 66.43 on Friday. Agios Pharmaceuticals, Inc. has a 52-week low of $39.24 and a 52-week high of $67.74. The stock has a 50 day moving average of $60.25 and a 200 day moving average of $54.45. The firm’s market capitalization is $3.21 billion.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.78) EPS for the quarter, missing analysts’ consensus estimates of ($1.57) by ($0.21). Agios Pharmaceuticals had a negative return on equity of 68.15% and a negative net margin of 502.12%. The business had revenue of $11.30 million during the quarter, compared to the consensus estimate of $10.68 million. During the same quarter in the previous year, the firm earned ($1.47) earnings per share. The firm’s revenue for the quarter was up 62.1% compared to the same quarter last year. On average, analysts predict that Agios Pharmaceuticals, Inc. will post ($7.07) EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this piece of content on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The correct version of this piece of content can be viewed at https://www.chaffeybreeze.com/2017/09/17/lewis-clayton-jr-cantley-sells-4000-shares-of-agios-pharmaceuticals-inc-agio-stock.html.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Bank of Montreal Can raised its holdings in shares of Agios Pharmaceuticals by 11.7% in the 1st quarter. Bank of Montreal Can now owns 2,068 shares of the biopharmaceutical company’s stock worth $121,000 after purchasing an additional 216 shares in the last quarter. Blue Sky Asset Management LLC bought a new stake in shares of Agios Pharmaceuticals in the 1st quarter worth approximately $129,000. Russell Investments Group Ltd. raised its holdings in shares of Agios Pharmaceuticals by 163.9% in the 1st quarter. Russell Investments Group Ltd. now owns 2,549 shares of the biopharmaceutical company’s stock worth $149,000 after purchasing an additional 1,583 shares in the last quarter. QS Investors LLC bought a new stake in shares of Agios Pharmaceuticals in the 2nd quarter worth approximately $144,000. Finally, Cubist Systematic Strategies LLC raised its holdings in shares of Agios Pharmaceuticals by 1,041.0% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 3,423 shares of the biopharmaceutical company’s stock worth $176,000 after purchasing an additional 3,123 shares in the last quarter. Institutional investors and hedge funds own 94.30% of the company’s stock.

Several research analysts have weighed in on the stock. Royal Bank Of Canada assumed coverage on shares of Agios Pharmaceuticals in a research report on Thursday. They set an “outperform” rating and a $78.00 target price on the stock. Canaccord Genuity set a $90.00 target price on shares of Agios Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, August 2nd. ValuEngine upgraded shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. Needham & Company LLC upped their target price on shares of Agios Pharmaceuticals from $54.00 to $72.00 and gave the stock a “buy” rating in a research report on Thursday, August 10th. Finally, Oppenheimer Holdings, Inc. reiterated an “outperform” rating and issued a $83.00 price target (up from $75.00) on shares of Agios Pharmaceuticals in a research report on Thursday, August 10th. Four research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $75.11.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

Insider Buying and Selling by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply